July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
The role of a novel metabolic regulator in human retinal pigment epithelial cell function
Author Affiliations & Notes
  • Sze Yuan Ho
    NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore
  • Beiying Qiu
    Institute of Molecular and Cell Biology, Singapore
  • Gemmy Chui Ming Cheung
    Singapore Eye Research Institute, Singapore, Singapore
  • Tien Yin Wong
    Singapore Eye Research Institute, Singapore, Singapore
    Ophthalmology & Visual Sciences Academic Clinical Program (ACP), Duke-NUS Medical School, Singapore, Singapore
  • Wan Jin Hong
    Institute of Molecular and Cell Biology, Singapore
  • Xiaomeng Wang
    NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore
    Institute of Molecular and Cell Biology, Singapore
  • Footnotes
    Commercial Relationships   Sze Yuan Ho, None; Beiying Qiu, None; Gemmy Cheung, Allergan (S), Bayer (C), Bayer (F), GlaxoSmith Kline (F), Novartis (C), Novartis Roche (F), Topcon (S); Tien Wong, Abbott (C), Abbott (F), Allergan (C), Allergan (F), Bayer (C), Bayer (F), Genentech (C), Genentech (F), Novartis (C), Novartis (F), Pfizer (C), Pfizer (F), Roche (C), Roche (F); Wan Jin Hong, None; Xiaomeng Wang, None
  • Footnotes
    Support  BMRC-SPF-SIPRAD
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sze Yuan Ho, Beiying Qiu, Gemmy Chui Ming Cheung, Tien Yin Wong, Wan Jin Hong, Xiaomeng Wang; The role of a novel metabolic regulator in human retinal pigment epithelial cell function. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1947.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, anti-vascular endothelial growth factor (VEGF) therapy is the first line treatment for neovascular age-related macular degeneration (nAMD). However, a substantial number of patients are not responsive to the treatment or may develop resistance over time. Furthermore, subretinal fibrosis can develop in approximately 50% of patients after two years of anti-VEGF treatment. Epithelial-mesenchymal transition (EMT) in retinal pigment epithelial cells (RPECs) was reported to play a key role in subretinal fibrosis associated with nAMD. In this study, we aim to investigate the impact of a novel lipase, SIPRAD007, on RPEC function.

Methods : Trypan blue exclusion and Ki-67 proliferation assays were performed to study the role of SIPRAD007 on the viability and proliferation of immortalised human RPECs, ARPE-19. The effect of SIPRAD007 on TGFβ1-induced expression of cytostatic and fibrotic genes was studied by real-time quantitative polymerase chain reaction (RT-qPCR) and/or Western blot analysis.

Results : Our study showed a significant reduction in the viability and proliferation of SIPRAD007 siRNA transfected ARPE-19 cells as compared to scrambled siRNA-treated control cells by 14.2 ± 2.7% (n=4) and 46.3 ± 12.9% (n=3) respectively. This observation was supported by an increased expression of cell cycle inhibitors, p15 and p21, in SIPRAD007 knockdown ARPE-19 cells. Furthermore, the siSIPRAD007-treated ARPE-19 cells were more responsive to TGFβ1-induced expression of connective tissue growth factor (CTGF) and plasminogen activator inhibitor-1 (PAI-1).

Conclusions : Our results demonstrated an important role of SIPRAD007 in RPEC viability, proliferation and the expression of fibrotic markers, including PAI-1 and CTGF.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

The protein levels of CTGF and PAI-1 were significantly upregulated in TGFβ1-treated siSIPRAD007 transfected ARPE-19 cells. Ordinary one-way ANOVA followed by Tukey’s multiple comparisons test was used for statistical analysis. *P < 0.05. Data are expressed as mean ± SEM (n ≥ 3).

The protein levels of CTGF and PAI-1 were significantly upregulated in TGFβ1-treated siSIPRAD007 transfected ARPE-19 cells. Ordinary one-way ANOVA followed by Tukey’s multiple comparisons test was used for statistical analysis. *P < 0.05. Data are expressed as mean ± SEM (n ≥ 3).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×